4D Molecular Therapeutics, Inc. (4DMT), is a trailblazing clinical-stage biopharma enterprise that is pioneering genetic therapies with a bold vision to transform lives affected by severe genetic diseases. Founded in 2013 and headquartered in Emeryville, California, 4DMT is tackling previously untreatable genetic disorders with transformative next-generation therapeutics.
A powerhouse of industry-leading expertise in vector discovery, gene therapy, biologics development, and manufacturing, 4DMT's focus is on creating precisely targeted and disease-specific delivery vectors for gene therapy. Their unique Therapeutic Vector Evolution platform generates powerful adeno-associated virus (AAV) vectors which deliver genes directly into the cells of patients.
At the heart of 4D Molecular Therapeutics’ is an innovative platform, known as Therapeutic Vector Evolution. This revolutionary approach in genetic medicine allows 4DMT to generate and optimize a personalized genetic therapy vector for any disease. The platform gives 4DMT the unprecedented capability to design corrective gene vectors precisely, choosing from over a hundred million vector sequences. It further enables tailoring vectors for particular patient populations, with specific therapeutic aims like complex retinal diseases, certain muscle diseases, and numerous others.
4DMT's core strategy relies on focused therapeutic areas: ophthalmology, cardiology, and pulmonology, and has developed several leading programs in these therapeutic areas. The company's prime product candidates include 4D-125 for X-linked retinitis pigmentosa (XLRP), 4D-110 for choroideremia, both retinal diseases, part of its robust ophthalmology portfolio.
4DMT also leverages collaborations and partnerships with leading pharmaceutical companies and research institutions to maximize its reach and impact. Its strategic collaboration with Roche for 4D-125 and 4D-110 is one such example, illustrating the firm’s ambition and credibility in the market.
Indeed, 4D Molecular Therapeutics is redefining the boundaries of genetic therapy. By unlocking the full potential of gene therapy through its innovative platform, it is ushering in a new era of precision medicine aimed at offering hope and improved quality of life for patients with severe genetic diseases. Its cutting-edge science, unique therapeutic design, and unwavering dedication to patients truly set 4DMT apart in the world of biopharmaceuticals.